Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Audentes Therapeutics Inc.

Division of Astellas Pharma Inc.
www.audentestx.com

Latest From Audentes Therapeutics Inc.

Japan 2010s In Review: Specialize, Focus, Innovate

Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.

Japan Reimbursement

2019’s Top Biopharma Deal-Makers

Gene therapy and targeted oncology treatments dominated the biggest acquisitions of the year. Boehringer Ingelheim and Roche were the most active big pharma in-licensers. Cancer and neurology were the focus of most alliances and financings.

Deals Market Intelligence

Finance Watch: Expect A Busy First Half For 2020 IPOs

Public Company Edition: At the J.P. Morgan Healthcare Conference and Biotech Showcase it was noted that the US IPO market is likely to be less active in the second half of the year as election risk chills investment. Also, Apellis leads recent follow-on offerings.

Financing Business Strategies

Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem

The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?

Japan Gene Therapy
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cardiovascular
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Astellas Pharma Inc.
  • Senior Management
  • Natalie C Holles, Pres. & CEO
    Thomas Soloway, SVP, CFO
    Edward R Conner, MD, SVP, CMO
    Eric B Mosbrooker, SVP, Chief Commercial Officer
  • Contact Info
  • Audentes Therapeutics Inc.
    Phone: (415) 818-1001
    600 California St., 17th Fl.
    San Francisco, CA 94018
    USA
UsernamePublicRestriction

Register